MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
1.031
+0.021
+2.04%
Opening 13:38 09/24 EDT
OPEN
1.030
PREV CLOSE
1.010
HIGH
1.080
LOW
1.007
VOLUME
27.96K
TURNOVER
--
52 WEEK HIGH
2.250
52 WEEK LOW
0.4912
MARKET CAP
95.83M
P/E (TTM)
-2.1665
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTOR last week (0914-0918)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 5d ago
Weekly Report: what happened at CTOR last week (0907-0911)?
Weekly Report · 09/14 10:19
Weekly Report: what happened at CTOR last week (0831-0904)?
Weekly Report · 09/07 10:13
Weekly Report: what happened at CTOR last week (0824-0828)?
Weekly Report · 08/31 10:20
Weekly Report: what happened at CTOR last week (0817-0821)?
Weekly Report · 08/24 10:20
Citius Oncology GAAP EPS of -$0.08 beats by $0.11, revenue of $1.5M misses by $4.27M
Seeking Alpha · 08/17 12:15
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/17 12:06
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.